Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

The hormone refractory prostate cancer clinical trial market research report provides an overview and top-line data relating to the clinical trials of hormone refractory prostate cancer. The report includes an overview of trials count and their average enrollment in top countries conducted globally. It also includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials (based on the number of ongoing trials).

Hormone Refractory Prostate Cancer Clinical Trials Market Distribution by Regions and Countries

The top regions in the hormone refractory prostate cancer clinical trials market are North America, Asia Pacific, the Middle East and Africa, Europe, and South and Central America. Most of the clinical trials were conducted in North America.

In the country-wise analysis, The US has the highest number of hormone refractory prostate cancer clinical trials, as of September 2022. Germany has the highest average patient enrollment of hormone refractory prostate cancer clinical trials, as of September 2022. 

G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, the United Kingdom has the highest proportion of hormone refractory prostate cancer in oncology clinical trials as of September 2022.

E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Mexico has the highest proportion of hormone refractory prostate cancer in oncology clinical trials as of September 2022.

Hormone Refractory Prostate Cancer Clinical Trials Market Analysis, By Regions

Hormone Refractory Prostate Cancer Clinical Trials Market Analysis, By Regions

For more regional insights on the hormone refractory prostate cancer clinical trials market, download a free report sample

Hormone Refractory Prostate Cancer Clinical Trials Market Segmentation by Sponsor Types

The key sponsor types in the hormone refractory prostate cancer clinical trials market are the company, institution, and government. Out of them, the company segment dominates the market.

Hormone Refractory Prostate Cancer Clinical Trials Market Analysis, by Sponsor Types

Hormone Refractory Prostate Cancer Clinical Trials Market Analysis, by Sponsor Types

To know more about key sponsor types in the hormone refractory prostate cancer clinical trials market, download a free report sample

Competitive Landscape

The leading companies in the hormone refractory prostate cancer clinical trials market are Johnson & Johnson, Sanofi, Astellas Pharma Inc, Bayer AG, Pfizer Inc, Bristol-Myers Squibb Co, Novartis AG, AstraZeneca Plc, Merck & Co Inc, and Takeda Pharmaceutical Co Ltd. Johnson & Johnson sponsored the highest number of hormone refractory prostate cancer clinical trials.

Hormone Refractory Prostate Cancer Clinical Trials Market Analysis, by Leading Companies

Hormone Refractory Prostate Cancer Clinical Trials Market Analysis, by Leading Companies

To know more about leading companies in the hormone refractory prostate cancer clinical trials market, download a free report sample 

Hormone Refractory Prostate Cancer Clinical Trials Market Report Overview

Key Regions North America, Asia Pacific, The Middle East and Africa, Europe, and South and Central America
Key Countries The US, United Kingdom, Canada, France, Spain, China, Germany, Australia, Italy, and Japan
Key Sponsor Types Company, Institution, and The Government
Leading Companies Johnson & Johnson, Sanofi, Astellas Pharma Inc, Bayer AG, Pfizer Inc, Bristol-Myers Squibb Co, Novartis AG, AstraZeneca Plc, Merck & Co Inc, and Takeda Pharmaceutical Co Ltd

Scope

The report provides:

  • A snapshot of the global clinical trials landscape
  • Top level data related to the clinical trials by region, country, trial status, trial phase, sponsor type, and end point status
  • Reviews of top companies involved and enlists all trials pertaining to the company
  • All the unaccomplished trials with the reason for unaccomplishment
  • Enrollment trends for the past five years
  • Latest news for the past three months

Reasons to Buy

  • Assists in formulating key business strategies with regard to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities
  • Supports understanding of trial count and enrollment trends by country in the global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted trials
  • Facilitates clinical trial assessment of the indication on a global, regional, and country level

Table of Contents

Table of Contents

List of Tables

List of Figures

Report Guidance

GlobalData Clinical Trials Report Coverage

Clinical Trials by Region

Clinical Trials and Average Enrollment by Country

Clinical Trials by G7 Countries: Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials

Prominent Drugs

Clinical Trial Profile Snapshots

Appendix

Abbreviations

Definitions

Research Methodology

Secondary Research

About GlobalData

Contact Us

Disclaimer

Source

Table

List of Tables

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Region, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2022*

Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, G7 Countries (%), 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*

Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, E7 Countries (%), 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Phase, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-2021

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*

Figures

List of Figures

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Region (%), 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2022*

Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, G7 Countries (%), 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2022*

Proportion of Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer to Oncology Clinical Trials, E7 Countries (%), 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2017-20121

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2022*

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2022*

GlobalData Methodology

Frequently asked questions

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update in real time.

  • Access a live Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.